The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
about
Lurasidone for the treatment of bipolar depression: an evidence-based reviewSynthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychoticsThe impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.Genetic variations in the serotoninergic system contribute to body-mass index in Chinese adolescents.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label studyMulti-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain.Evidence review and clinical guidance for the use of ziprasidone in Canada.Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.High-throughput electronic biology: mining information for drug discovery.Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndromeA potential mechanism underlying atypical antipsychotics-induced lipid disturbancesAssociation between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics.Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Drug-induced hyperphagia: what can we learn from psychiatric medications?Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases.Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain.Sex-specific differences in side effects of psychotropic drugs: genes or gender?Pharmacogenetic considerations in the treatment of psychiatric disorders.From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.Treatment-emergent adverse events associated with atypical antipsychotics.Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapineThe effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder.Pharmacogenetics of second-generation antipsychotics.HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.The development of lurasidone for bipolar depression.Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors.Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report.Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain.Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.
P2860
Q26796437-DB99BAA8-3D18-48F3-818A-6AADC64C5CC1Q28483019-B14E9976-2BF9-4E66-B513-184B9354C1ACQ34197980-E59D75E9-812F-4008-BD54-AF799A2FFD15Q34497909-C1682A13-CF92-4082-8AED-F9235A8D9E49Q34542303-5765B8F6-3D8F-444F-8CEC-11C53D63E3F3Q34648230-D52BFBA2-BDA5-472E-8244-B7A9ECD1D870Q35191252-6888F2EB-655B-4414-894C-6032F16E6135Q35700356-24E74A21-729E-4412-9913-EA153A91A195Q35973931-9D6255F6-E3A1-4644-B74D-7EFFF368C1A2Q35992330-89491F99-7D34-4CB7-A6F7-8E06780CA1EDQ36441507-8BD5E9EF-207E-4559-A9D4-8C1EE112ABB0Q36588607-00F8C9FD-6573-423E-9272-C143F2FD05FCQ36593819-C9D9D2E7-919A-4AD6-8503-B8D542596C39Q36748142-E6739E8B-7162-49E4-B513-13DBCBAB8E9AQ36852489-64656EBB-A722-4760-8EE8-202F0EC41166Q37043479-1B606A48-5467-4530-B67A-E1964B424A59Q37058653-15392F4A-762A-44D9-B65C-87A2DB35B3CFQ37087294-5ABB52F7-986F-4FDC-80AE-C83AFAD0BB85Q37095956-C0619A4D-C3E6-4412-9E64-6786421C067BQ37160453-E50784FB-E343-4C48-ACE9-A03D1F506A22Q37254782-10767D20-80E2-4F8D-AED7-77211CCA6F90Q37464848-797C3BE5-4500-4BD3-95C6-A62F41EB5249Q37515292-7172D81F-0673-498A-8458-164E3F54AB9DQ37598900-07BFC017-D7B7-4494-ABBA-4FABF01A8281Q37681573-00967728-C3FE-44F4-A521-B5D314CF7378Q37806982-B90892E1-C4BE-4C74-A230-C6CB18D87AB3Q37865505-0487A933-0E15-4CA1-802A-DDA47DCDF52FQ37963571-1AE127BB-B0BD-4DA9-B866-6BE229EA5848Q37981271-F9811BBD-0367-4152-8BB0-BCE8E3ADF36AQ38132163-EB370028-3F82-4602-A677-3436172F88FCQ38208032-008F7B53-4A62-4B20-8154-84BFEDFDCC74Q38217628-9A16BBCE-E360-45C1-853C-DD1A7DA08CCEQ38242739-092579C6-0C1B-46EC-9950-D8DE4C5A0881Q38697937-6C20F418-A878-4F3F-8627-EC70D5FFECD1Q38789687-FE7510C2-CECF-4144-9082-DD0A6CA5E1FAQ39035865-08F79BE6-674F-4167-B1EF-6C3C82271AADQ43053801-8CADEB1A-3CFE-4FB8-BEFA-8218672CEAE1Q45252599-E677F597-FD53-42F1-B19B-D8365EE0E2A1Q46356344-2FDEC8D4-A785-48E8-8A95-E5DC1C2E70D4Q46444830-7AF083DD-5CBA-46DE-AAF1-3439894743C8
P2860
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@ast
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@en
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@nl
type
label
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@ast
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@en
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@nl
prefLabel
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@ast
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@en
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
@nl
P2860
P356
P1476
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics
@en
P2093
Matthew J Hill
Shona L Kirk
P2860
P356
10.1177/1359786806066040
P407
P433
P577
2006-07-01T00:00:00Z